Pharma BD Deal Intelligence
Regeneron Pharmaceuticals, Inc. / 2seventy bio, Inc.
2024 · Asset Purchase · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2029 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jan 29, 2024
- Deal type Asset Purchase
Related deals
- Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. (2019)
- Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (2026)
- Regeneron Pharmaceuticals, Inc. / Sanofi S.A. (Libtayo global rights) (2022)
- Regeneron Pharmaceuticals, Inc. / 23andMe, Inc. (2025)
- Regeneron Pharmaceuticals, Inc. / Parabilis Medicines, Inc. (2026)
- Regeneron Pharmaceuticals, Inc. / CytomX Therapeutics, Inc. (2022)
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2024 deals · Regeneron Pharmaceuticals, Inc. deals